+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tyrosine Kinase Inhibitors Market by Indication (Breast Cancer, Chronic Myeloid Leukemia, Non Small Cell Lung Cancer), Target (Alk, Bcr-Abl, EGFR), Generation, Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Tyrosine Kinase Inhibitors Market by Indication (Breast Cancer, Chronic Myeloid Leukemia, Non Small Cell Lung Cancer), Target (Alk, Bcr-Abl, EGFR), Generation, Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Tyrosine Kinase Inhibitors Market by Indication (Breast Cancer, Chronic Myeloid Leukemia, Non Small Cell Lung Cancer), Target (Alk, Bcr-Abl, EGFR), Generation, Route Of Administration, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715482
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The tyrosine kinase inhibitors market is experiencing sustained momentum as innovation, strategic alliances, and evolving global demands drive development and define the route to commercial success for industry stakeholders.

Market Snapshot: Tyrosine Kinase Inhibitors Market

The Tyrosine Kinase Inhibitors Market grew from USD 63.46 billion in 2024 to USD 68.21 billion in 2025. It is expected to continue growing at a CAGR of 7.14%, reaching USD 96.02 billion by 2030.

Scope & Segmentation

  • Indications: Breast cancer, chronic myeloid leukemia, non-small cell lung cancer, renal cell carcinoma
  • Therapy Lines: First line, second line, third line approaches for relevant cancers
  • Targets: Alk, Bcr-Abl (first, second, and third generation), EGFR (first, second, and third generation), Vegfr
  • Generations: First, second, and third generation inhibitors across the main molecular subtypes
  • Route of Administration: Intravenous, oral
  • Distribution Channel: Hospital pharmacies, retail pharmacies
  • Geography: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (UK, Germany, France, and additional countries), Asia-Pacific (China, India, Japan, Australia, South Korea, and more)
  • Technology Platforms: Structural drug design, genomic profiling, liquid biopsy, digital health and trial monitoring
  • Key Market Players: AstraZeneca PLC, Novartis AG, AbbVie Inc., Eisai Co., Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim International GmbH, Johnson & Johnson

Key Takeaways for Senior Decision-Makers

  • Precision oncology continues to benefit from tyrosine kinase inhibitors designed around patient-specific molecular targets, expanding the realm of personalized therapies.
  • Strategic alliances between pharmaceutical companies, biotechnology firms, and academic centers accelerate the transition from discovery to late-stage clinical evaluation, generating advanced pipeline assets and innovative combinations.
  • Adaptation to payer and regulatory trends is essential; flexible approval frameworks, real-world evidence integration, and targeted pricing help firms stay ahead in competitive settings.
  • Distinct generational advancements within inhibitor classes address acquired resistance and safety, supporting continued lifecycle management and portfolio differentiation.
  • Regional variability in regulatory timelines, reimbursement processes, and clinical adoption underscores the need for customized market access strategies and localized manufacturing relationships.
  • Digital platforms, artificial intelligence, and process intensification are increasingly critical for optimizing development, pharmacovigilance, and supply chain efficiency across global operations.

Tariff Impact: United States Policy Shifts

From 2025, new United States tariffs on imported active pharmaceutical ingredients and essential raw materials are altering cost structures and operational planning for tyrosine kinase inhibitor manufacturers. These tariffs incentivize companies to diversify supply bases, evaluate nearshoring, and invest in continuous manufacturing, helping contain costs while supporting sustained delivery and access. Companies utilizing robust risk management—including dual sourcing and inventory optimization—are better equipped to adapt amid customs changes and regulatory updates. This climate further accelerates adoption of localized partnerships and advanced analytics for demand forecasting to maintain throughput and service continuity.

Methodology & Data Sources

This analysis combines comprehensive secondary research with targeted primary interviews involving clinicians, regulatory specialists, and supply chain leaders. Peer-reviewed literature, clinical trial registries, regulatory documents, and patent data form the knowledge foundation. Insights are validated through structured qualitative interviews, competitive benchmarking, and value chain mapping to assess market scenarios and risk profiles.

Why This Report Matters

  • Provides actionable insights on evolving therapeutic, clinical, and commercial strategies for tyrosine kinase inhibitors across key geographies.
  • Equips decision-makers with intelligence on pipeline advancement, operational optimization, and approaches for regulatory adaptation—including management of trade disruption and patient access challenges.
  • Facilitates cross-team planning, leveraging up-to-date trends in innovation, digital integration, and alliance partnership structures to guide strategic investments.

Conclusion

Stakeholders equipped with this market intelligence can better position their organizations to respond to technological advances, policy shifts, and emerging market opportunities. Effective strategies will rely on cross-functional alignment and continuous adaptation to changing regulatory and economic environments.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Development of third-generation TKIs targeting T790M-resistant EGFR mutations
5.2. Increasing investment in combination therapies pairing TKIs with immune checkpoint inhibitors
5.3. Emergence of allosteric ABL kinase inhibitors to overcome resistance from BCR-ABL mutations
5.4. Adoption of genomic profiling in clinical practice to personalize TKI treatment regimens
5.5. Strategic partnerships between biotech innovators and pharma giants to accelerate TKI pipeline development
5.6. Real world evidence studies assessing safety and efficacy of TKIs in older cancer patient cohorts
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tyrosine Kinase Inhibitors Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.3. Chronic Myeloid Leukemia
8.3.1. First Line
8.3.2. Second Line
8.3.3. Third Line
8.4. Non Small Cell Lung Cancer
8.4.1. First Line
8.4.2. Second Line
8.4.3. Third Line
8.5. Renal Cell Carcinoma
9. Tyrosine Kinase Inhibitors Market, by Target
9.1. Introduction
9.2. Alk
9.3. Bcr-Abl
9.3.1. First Generation
9.3.2. Second Generation
9.3.3. Third Generation
9.4. EGFR
9.4.1. First Generation
9.4.2. Second Generation
9.4.3. Third Generation
9.5. Vegfr
10. Tyrosine Kinase Inhibitors Market, by Generation
10.1. Introduction
10.2. First Generation
10.3. Second Generation
10.4. Third Generation
11. Tyrosine Kinase Inhibitors Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Tyrosine Kinase Inhibitors Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Retail Pharmacies
13. Americas Tyrosine Kinase Inhibitors Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Tyrosine Kinase Inhibitors Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Tyrosine Kinase Inhibitors Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AstraZeneca PLC
16.3.2. Novartis AG
16.3.3. AbbVie Inc.
16.3.4. Eisai Co., Ltd.
16.3.5. Pfizer Inc.
16.3.6. F. Hoffmann-La Roche Ltd
16.3.7. Bristol-Myers Squibb Company
16.3.8. Bayer AG
16.3.9. Boehringer Ingelheim International GmbH
16.3.10. Johnson & Johnson
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TYROSINE KINASE INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. TYROSINE KINASE INHIBITORS MARKET: RESEARCHAI
FIGURE 26. TYROSINE KINASE INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 27. TYROSINE KINASE INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 28. TYROSINE KINASE INHIBITORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TYROSINE KINASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 124. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 125. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 126. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 127. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 128. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 129. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 130. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 131. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 132. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 133. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 134. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 135. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 142. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 143. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 144. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 145. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 146. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 147. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 149. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 150. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 151. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 152. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 153. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 234. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 235. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 236. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 237. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 238. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 239. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 240. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 241. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 242. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 243. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 244. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 245. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 252. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 253. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 254. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 255. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 256. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 257. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 258. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 259. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 260. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 261. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 262. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 263. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 288. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 289. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 290. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 291. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 292. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 293. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 294. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 295. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2024 (USD MILLION)
TABLE 296. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2025-2030 (USD MILLION)
TABLE 297. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 298. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 299. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 306. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 307. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 308. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 309. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2024 (USD MILLION)
TABLE 310. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025-2030 (USD MILLION)
TABLE 311. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2024 (USD MILLION)
TABLE 312. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2025-2030 (USD MILLION)
TABLE 313. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tyrosine Kinase Inhibitors market report include:
  • AstraZeneca PLC
  • Novartis AG
  • AbbVie Inc.
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 68.21 Billion
Forecasted Market Value ( USD ) by 2030 $ 96.02 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Tyrosine Kinase Inhibitors - Global Strategic Business Report - Product Image

Tyrosine Kinase Inhibitors - Global Strategic Business Report

  • Report
  • 290 Pages
  • Global
From
Tyrosine Kinase Inhibitors Market Report 2025 - Product Image

Tyrosine Kinase Inhibitors Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Bruton's Tyrosine Kinase Inhibitor Pipeline Analysis Report 2025 - Product Image

Bruton's Tyrosine Kinase Inhibitor Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Bruton's Tyrosine Kinase Inhibitors Market by Type (Irreversible Covalent, Reversible Non-Covalent), Indication (Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Waldenström's Macroglobulinemia), Line of Therapy, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Bruton's Tyrosine Kinase Inhibitors Market by Type (Irreversible Covalent, Reversible Non-Covalent), Indication (Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Waldenström's Macroglobulinemia), Line of Therapy, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Bruton Tyrosine Kinase Inhibitors Market by Product (Acalabrutinib, Ibrutinib, Zanubrutinib), Indication (Autoimmune Disorder, Hematological Malignancy), Line of Therapy, Route, Distribution Channel - Global Forecast 2025-2030 - Product Image

Bruton Tyrosine Kinase Inhibitors Market by Product (Acalabrutinib, Ibrutinib, Zanubrutinib), Indication (Autoimmune Disorder, Hematological Malignancy), Line of Therapy, Route, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From

About the Tyrosine Kinase Inhibitors Market

Tyrosine Kinase Inhibitors (TKIs) are a class of pharmaceuticals that target tyrosine kinase enzymes, which are involved in the activation of signal transduction pathways that ultimately lead to cell division and proliferation. The dysregulation of tyrosine kinases is a common feature in the pathogenesis of various types of cancer, leading to unchecked cell growth and tumor development. TKIs are therefore an important class of anticancer agents that have reshaped the drug discovery landscape, especially in the treatment of cancers with identifiable molecular targets. In the realm of drug discovery, the market for TKIs has matured with the approval of numerous agents that cover a wide spectrum of targets. Research and innovation focus on improving the efficacy and reducing the side effects, which can include kinome non-selectivity leading to off-target effects. Moreover, the emergence of resistance to first-generation TKIs has spurred the development of second- and third-generation inhibitors that aim to overcome resistance by binding to the kinase domain of mutant enzymes. Several companies are prominent players in the TKI market, frequently associated with pioneering research and the introduction of novel therapeutics. Key names include Novartis, Pfizer, Roche, AstraZeneca, and Bristol Myers Squibb. These companies not only invest heavily in research and development of TKIs but also in the strategic acquisition of smaller biotech firms, partnerships, and collaborations to expand their portfolios and address the diverse needs of patients with cancer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.